Best Probiotic for Men Evidence-graded, strain by strain

Probiotics with antibiotics: diarrhoea, and the one strong reason

This is the strongest evidence-backed reason a man might take a probiotic, and the strain that earns it is not in any men's product at a knowable dose.

, Independent analyst Last verified Disclosures

This is the page behind the strongest reason on this site to take a probiotic at all, and it is also where the limits of that reason are set out: the strain class, not the product, is what earns Grade B, and the ranking table records no buyable product for it.

Antibiotic-associated diarrhoea — the one strong reason

S. boulardii for AAD in adults is significant and well-powered: 17.4% → 8.2%, RR 0.49 (95% CI 0.38–0.63), 15 RCTs, n=3,114 (PMID 26216624). That is the best-powered adult probiotic result in this entire corpus.

Do not switch outcomes mid-argument, in either direction. S. boulardii fails on CDAD in adults: RR 0.80 (0.47–1.34), 9 RCTs, n=1,441 (significant only in children). LGG (ATCC 53103) fails on AAD in adults: RR 0.48 (95% CI 0.20–1.15), 6 RCTs, n=863, low certainty — while remaining significant in children (RR 0.48, 0.26–0.89) and in H. pylori eradication regimens (RR 0.26, 0.11–0.59) (PMID 26365389). Both of those source papers state positive conclusions overall; this reading disagrees with them on the basis of their own subgroup tables, and says so.

At class level, the C. difficile result is real, small, and points at no product. Cochrane 2025: 47 studies, n=15,260; CDAD incidence from 38 trials / 13,179 participants at 1.6% (110/6,787) versus 3.2% (203/6,392), RR 0.50 (95% CI 0.38–0.64), NNT 65 (48–97), low certainty. "We noted authors' affiliation with a probiotic company and financial support received from probiotic companies in 28 studies." That is down from RR 0.40 / NNT 42 in 2017 — partly new data, partly a lower control event rate (4.0%→3.2%) — but the confidence intervals overlap substantially, so it is not right to call the newer estimate significantly weaker (PMID 40931979; PMID 29257353). The same review's null results deserve equal billing: adverse events RR 0.86 (0.72–1.01); C. difficile colonisation RR 0.87 (0.68–1.11); hospital length of stay MD −0.07 days (−0.35 to 0.21). "Restores your microbiome after antibiotics" was never measured; what was measured is null.

The two largest and most independent tests in the field are null. PLACIDE: 2,981 randomised, inpatients ≥65, NIHR HTA-funded — AAD 10.8% versus 10.4%, RR 1.04 (0.84–1.28), p=0.71; C. difficile diarrhoea 0.8% versus 1.2%, RR 0.71 (0.34–1.47), p=0.35 (PMID 23932219). PREVENT CDI-55+: a stepped-wedge cluster trial across four hospitals, 269,811 admissions / 1,712,114 patient-days — adjusted healthcare-associated CDI IRR 0.92 (0.68–1.23), with the unadjusted positivity benefit (IRR 0.75, P<.001) vanishing on adjustment (PMID 38073551). ACG 2021 recommends against probiotics for CDI prevention in patients being treated with antibiotics (conditional recommendation, moderate quality).

One recent trial cuts hard the other way, and it must be carried. A 2024 multicentre, double-blind, placebo-controlled adult RCT in Bulgaria: 564 randomised (285 versus 279), AAD 9.2% versus 25.3%, P<.001, ARR 16%, NNT 6 (95% CI 4.55–10.49) (PMID 39529939; NCT05607056). It does not overturn "the largest tests are null" — PLACIDE is five times larger — but it breaks the implied trajectory that more rigour always deflates the effect. And it is simultaneously the best proof of the strain-precision thesis: the product discloses no strain designators at all, genus and species only, so no consumer can reproduce it. COI: "All authors have delivered scientific lectures on a given problem for various pharmaceutical companies, including Neopharm Bulgaria."

Species labels carry no information, and this category proves it. Three different L. acidophilus strains produced: a null in a 2,981-patient trial, a null at RR 0.79 (0.47–1.33), and a positive in single trials. Also note that the Actimel trial's strain is L. casei DN-114 001 (Danone), not L. casei Shirota (Yakult) — 1,760 screened → 135 randomised → 113 analysed, ~46% male, AAD 12% versus 34%, p=0.007 (PMID 17604300).

No men-only AAD trial exists, and no pre-specified sex-stratified efficacy analysis exists in this field. The only quantitative sex evidence is a trial-level meta-regression (ecological, not individual): sex ratio p=0.76 across 51 articles / 60 comparisons / 9,569 participants (PMID 29511547). Separately, one trial pre-specified sex as a risk factor for AAD and found it null (PMID 26973849).

And for the specific case that brings men here: there is no probiotic RCT for antibiotic-prophylaxis diarrhoea around transrectal prostate biopsy. A broad PubMed search on 29 July 2026 returned 13 records, none of them a randomised trial of a probiotic for AAD or CDI prevention in that population.

Where these outcomes sit in the 22-row table

The grade is assigned on the hub’s 22-row table and argued above. The row s are reproduced here unchanged, so the grade a reader quotes from this page is the same grade the table carries. What a grade measures is set out under how the grades work: it is a statement about the strength of the evidence for a named strain, never a statement that a product does anything.

The rows of the 22-row outcome table this page is the long version of. Default order: as numbered in the full table. Sortable columns are marked; sorting needs JavaScript, the order above does not.
# Outcome Best grade at strain level The strain, and the trial behind it Buyable at the dose that was studied?
1 Diarrhoea while taking antibiotics Saccharomyces boulardii — AAD in adults, 17.4%→8.2%, RR 0.49 (0.38–0.63), 15 RCTs, n=3,114 (PMID 26216624) No — no S. boulardii single-organism product in our teardown set; the two products containing it bury it in a blend with no per-strain quantity
11 C. difficile diarrhoea during antibiotics Class-level only — RR 0.50 (0.38–0.64), NNT 65 (48–97), low certainty (PMID 40931979) N/A

The strains named above, and the labels in this audit that print them

Every row below is a line on a printed supplement panel, read off that product’s own teardown. A panel printing a designator is a fact about the panel. It is not evidence that the product was tested, that it delivers the amount that was studied, or that the strain does anything — several of the paragraphs above say in terms that it does not, and the dose is unknowable wherever the panel gives no per-organism quantity.

Saccharomyces boulardii, and CNCM I-745 where the panel prints it
L. rhamnosus GG (ATCC 53103)
L. casei DN-114 001

Not printed on any panel this audit has transcribed.

Scope, stated because an absence here is a published claim: this searches the organism slots transcribed from 156 of the 166 labels in the audit. A panel that is not fully transcribed can hide a line, so “not printed on any panel this audit has transcribed” is exactly that, and never “not sold anywhere”. Each product links to its own label audit, where the panel, the designator resolution and the arithmetic are set out in full.

Read next

This is the section published on the home page under #aad, relocated unchanged.